First Time Loading...

Suven Pharmaceuticals Ltd
NSE:SUVENPHAR

Watchlist Manager
Suven Pharmaceuticals Ltd Logo
Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
Watchlist
Price: 643.9 INR -0.27% Market Closed
Updated: May 13, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

11.7B
-10%
Revenue
Growth Rates:
1 Year
-13%
3 Years
+25%
5 Years
-
7 Years
-
10 Years
-
4.5B
-15%
Operating Income
Growth Rates:
1 Year
-11%
3 Years
+14%
5 Years
-
7 Years
-
10 Years
-
3.7B
-14%
Net Income
Growth Rates:
1 Year
-2%
3 Years
+5%
5 Years
-
7 Years
-
10 Years
-

Earnings Waterfall
Suven Pharmaceuticals Ltd

Revenue
11.7B INR
Cost of Revenue
-4.8B INR
Gross Profit
6.9B INR
Operating Expenses
-2.4B INR
Operating Income
4.5B INR
Other Expenses
-791.3m INR
Net Income
3.7B INR

Income Statement
Suven Pharmaceuticals Ltd

Rotate your device to view
Income Statement
Currency: INR
Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023
Revenue
Revenue
8 482
N/A
9 000
+6%
8 338
-7%
8 746
+5%
8 391
-4%
9 353
+11%
10 097
+8%
10 353
+3%
10 989
+6%
12 155
+11%
13 202
+9%
13 952
+6%
13 726
-2%
13 348
-3%
13 403
+0%
13 491
+1%
13 017
-4%
11 678
-10%
Gross Profit
Cost of Revenue
(3 387)
(3 552)
(3 197)
(3 628)
(3 483)
(3 791)
(4 153)
(4 567)
(4 897)
(5 537)
(5 503)
(5 961)
(5 919)
(5 832)
(5 683)
(5 796)
(5 343)
(4 825)
Gross Profit
5 095
N/A
5 448
+7%
5 141
-6%
5 118
0%
4 908
-4%
5 562
+13%
5 944
+7%
5 786
-3%
6 092
+5%
6 619
+9%
7 699
+16%
7 991
+4%
7 807
-2%
7 516
-4%
7 720
+3%
7 695
0%
7 674
0%
6 853
-11%
Operating Income
Operating Expenses
(1 325)
(1 378)
(1 528)
(1 425)
(1 505)
(1 605)
(1 856)
(1 692)
(1 782)
(1 847)
(2 294)
(2 250)
(2 314)
(2 433)
(2 532)
(2 357)
(2 353)
(2 353)
Selling, General & Administrative
(641)
(683)
(1 290)
(720)
(755)
(792)
(1 428)
(800)
(822)
(859)
(1 800)
(1 059)
(1 114)
(1 160)
(1 969)
(1 127)
(1 126)
(1 158)
Research & Development
0
0
0
(31)
(69)
(96)
(111)
(103)
(102)
(97)
(104)
(102)
(86)
(87)
(86)
(84)
(108)
(109)
Depreciation & Amortization
(226)
(227)
(239)
(253)
(272)
(304)
(316)
(336)
(352)
(370)
(391)
(416)
(445)
(462)
(477)
(488)
(486)
(491)
Other Operating Expenses
(458)
(468)
0
(422)
(409)
(414)
0
(453)
(505)
(521)
0
(673)
(669)
(724)
0
(658)
(633)
(596)
Operating Income
3 770
N/A
4 070
+8%
3 613
-11%
3 693
+2%
3 404
-8%
3 957
+16%
4 088
+3%
4 095
+0%
4 311
+5%
4 772
+11%
5 405
+13%
5 741
+6%
5 493
-4%
5 083
-7%
5 188
+2%
5 339
+3%
5 321
0%
4 500
-15%
Pre-Tax Income
Interest Income Expense
99
97
424
187
251
396
547
590
698
558
515
119
(47)
(53)
375
(51)
(53)
(52)
Gain/Loss on Disposition of Assets
0
0
1
0
0
0
0
0
0
0
(2)
0
0
0
(0)
0
0
0
Total Other Income
85
132
7
214
163
163
41
143
190
788
758
976
1 035
518
34
460
549
563
Pre-Tax Income
3 953
N/A
4 299
+9%
4 045
-6%
4 094
+1%
3 818
-7%
4 516
+18%
4 677
+4%
4 827
+3%
5 198
+8%
6 118
+18%
6 676
+9%
6 836
+2%
6 482
-5%
5 548
-14%
5 597
+1%
5 747
+3%
5 816
+1%
5 010
-14%
Net Income
Tax Provision
(1 011)
(1 122)
(875)
(928)
(841)
(982)
(1 053)
(1 068)
(1 210)
(1 665)
(2 138)
(2 274)
(2 168)
(1 758)
(1 484)
(1 504)
(1 498)
(1 302)
Income from Continuing Operations
2 942
3 176
3 170
3 166
2 977
3 534
3 623
3 759
3 988
4 453
4 538
4 563
4 313
3 790
4 113
4 243
4 318
3 709
Net Income (Common)
2 942
N/A
3 176
+8%
3 170
0%
3 166
0%
2 977
-6%
3 534
+19%
3 623
+3%
3 759
+4%
3 988
+6%
4 453
+12%
4 538
+2%
4 563
+1%
4 313
-5%
3 790
-12%
4 113
+9%
4 243
+3%
4 318
+2%
3 709
-14%
EPS (Diluted)
11.55
N/A
12.47
+8%
12.45
0%
12.43
0%
11.69
-6%
13.88
+19%
14.2
+2%
14.76
+4%
15.66
+6%
17.49
+12%
17.79
+2%
17.92
+1%
16.94
-5%
14.88
-12%
16.16
+9%
16.67
+3%
16.98
+2%
14.59
-14%

See Also

Summary
SUVENPHAR intrinsic value, competitors valuation, and company profile.
DCF Valuation
SUVENPHAR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SUVENPHAR stock valuation using valuation multiples.
Wall Street Estimates
SUVENPHAR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SUVENPHAR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 136,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.